Dr. Bryan James Schneider is a clinical professor specializing in medical oncology and internal medicine at the University of Michigan’s Rogel Cancer Center. As Section Head for the medical thoracic oncology team, Dr. Schneider’s areas of practice include lung cancer, esophageal cancer, mesothelioma, thymoma, and carcinoid tumors.
The Thoracic Oncology Team at Rogel Cancer Center that Dr. Schneider directs represents a gathering of professionals with profound expertise in Chest Wall Tumors, esophageal cancer, lung cancer, mediastinal tumors, mesothelioma, pulmonary nodules, and thymoma tumors. Their multidisciplinary approach sees them coordinate and consult on diagnosing each patient’s condition and identifying the best treatment option. The team meets weekly in the Multidisciplinary Lung Cancer Clinic and the Multidisciplinary Thoracic Oncology Conference.
Education and Career
Dr. Schneider began his educational journey at the University of Notre Dame, where he earned his undergraduate degree. From there he moved on to Indiana University School of Medicine where he earned his medical degree and completed his internship and residency in Internal Medicine. After serving as Chief Resident there, he completed a fellowship in Hematology/Oncology at the University of Michigan, then joined the faculty as an Assistant Professor.
Dr. Schneider spent several years as an Assistant Professor at Cornell University, where he was the Madeline and Stephen Anbinder Clinical Scholar in Hematology/Oncology and assistant professor of medicine.
Dr. Schneider is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has served as a member of the Experimental Therapeutics Study Section of the National Institutes of Health and serves on numerous other scientific medical committees, including the ASCO thoracic guideline advisory group and the steering committee for the National Cancer Center Network (NCCN) guidelines.
Dr. Schneider has varied areas of clinical research interest. He has co-authored over 64 peer-reviewed articles, including the recently-published article “Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update,” which was published in the Journal of Clinical Oncology. He has written several book chapters on the subject of lung cancer and has also participated in multiple clinical trials over the last several years.